Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.
Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A.
Oki Y, et al. Among authors: romaguera j.
Br J Haematol. 2015 Nov;171(4):463-70. doi: 10.1111/bjh.13603. Epub 2015 Jul 27.
Br J Haematol. 2015.
PMID: 26213141
Free PMC article.
Clinical Trial.